Drug Profile
Research programme: temozolomide/thalidomide nanoparticles - Pharmaco-Kinesis
Alternative Names: Temozolomide/thalidomide; Thalidomide/temozolomide; TNTLatest Information Update: 23 Mar 2023
Price :
$50
*
At a glance
- Originator Pharmaco-Kinesis Corporation
- Class Imidazoles; Phthalimides; Piperidones; Small molecules; Triazenes
- Mechanism of Action Alkylating agents; Angiogenesis inhibitors; DNA cross linking agents; DNA synthesis inhibitors; Tumour necrosis factor inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- Discontinued Glioma
Most Recent Events
- 23 Mar 2023 Discontinued - Preclinical for Glioma in USA (Parenteral)
- 28 Jun 2019 No recent reports of development identified for preclinical development in Glioma in USA (Parenteral, Infusion)
- 26 May 2015 Preclinical trials in Glioma in USA (Parenteral)